Samrat Pharmachem Ltd

Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 Aug 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 August 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 23 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Samrat Pharmachem Ltd has witnessed a significant shift in its valuation parameters, with key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios deteriorating sharply compared to historical averages and peer benchmarks. This change has coincided with a steep decline in the stock price, prompting a downgrade in its investment grade to Strong Sell by MarketsMOJO as of 19 Aug 2025.

Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 August 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 10 February 2026, providing investors with the latest insights into its performance and outlook.

Samrat Pharmachem Ltd’s valuation metrics have recently deteriorated, shifting from expensive to very expensive territory, raising concerns about its price attractiveness amid a challenging sector backdrop and subdued returns relative to benchmarks.

Samrat Pharmachem Ltd’s stock touched a fresh 52-week low of Rs.195.1 today, marking a significant decline amid ongoing challenges in its financial performance and market positioning. This new low reflects a continuation of the stock’s downward trajectory over the past year, with the share price now trading well below all key moving averages.

Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 August 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 30 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Samrat Pharmachem Ltd’s stock reached a fresh 52-week low of Rs.199 today, marking a significant decline amid ongoing challenges in the Pharmaceuticals & Biotechnology sector. The stock has underperformed its sector peers and benchmark indices, reflecting persistent pressures on the company’s financial and market metrics.

Samrat Pharmachem Ltd’s stock declined to a fresh 52-week low of Rs.206 on 21 Jan 2026, marking a significant milestone in its ongoing downward trajectory. The pharmaceutical and biotechnology company’s shares have underperformed both its sector and the broader market, reflecting persistent pressures on its financial and market performance.

Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 August 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 19 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Samrat Pharmachem Ltd’s stock declined sharply to a fresh 52-week low of Rs.210 on 12 Jan 2026, marking a significant milestone in its ongoing downward trajectory. The pharmaceutical company’s shares have underperformed both the sector and broader market indices, reflecting persistent pressures on its financial and market performance.

Samrat Pharmachem Ltd’s stock declined to a fresh 52-week low of Rs.222.05 on 7 January 2026, marking a significant downturn amid persistent underperformance relative to its sector and benchmark indices. The pharmaceutical and biotechnology company’s shares have been trading below all key moving averages, reflecting ongoing pressures on its valuation and financial metrics.

Samrat Pharmachem Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 19 Aug 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 07 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Samrat Pharmachem Ltd’s stock declined to a fresh 52-week low of Rs.224.95 on 29 Dec 2025, marking a significant milestone in its ongoing downward trajectory. The stock has underperformed its sector and benchmark indices, reflecting persistent pressures on its financial and market performance.

Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 19 August 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 25 December 2025, providing investors with the latest insights into the company’s performance and outlook.

Samrat Pharmachem’s stock price reached a fresh 52-week low of Rs.230.05 today, marking a significant decline amid a sustained downward trend. The stock has experienced a series of losses over the past four trading sessions, culminating in a cumulative return of -9.65% during this period, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.

Samrat Pharmachem's stock price reached a fresh 52-week low of Rs.237 today, marking a significant decline amid ongoing downward momentum. The pharmaceutical company’s shares have been under pressure, reflecting a series of financial and market factors that have influenced its performance over the past year.

Samrat Pharma, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting ongoing operational and financial challenges. This shift highlights the company’s current standing amid a difficult market environment and evolving investor perspectives.

Samrat Pharmachem's shares reached a fresh 52-week low of Rs.250 today, marking a significant decline amid broader market gains. The stock underperformed its sector and key benchmarks, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology space.